\
&
Contact us
\
&
Contact us
Background stories of how others approached and experienced their European Horizon funding trajectory.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
Read the full article for detailsPublished on • 1 year ago
These testimonials share at least one programme or target audience.
Funded under Horizon Europe (HORIZON-CL5-2023-D6-01-09), running from 2024 to 2028, CLARION (Building Climate-Resilient Ports for the Future) aims to contribute to shaping a sustainable future for the maritime sector by developing and implementing innovative climate adaptation solutions. Port of Antwerp-Bruges is one of the leading European ports involved in the project. Together with two other Flemish project partners, Brabo Group and the Antwerp Maritime Academy, Port of Antwerp-Bruges is developing demo cases that tackle real-life operational and training challenges posed by climate risks. Read more about the project in this testimonial.
